European Journal of Clinical Pharmacology

, Volume 35, Issue 1, pp 93–95 | Cite as

Accumulation of pinacidil N-oxide during chronic treatment with pinacidil

  • A. McBurney
  • J. A. Henry
  • J. W. Ward
Short Communications

Summary

The effects of acute and chronic administration of a slow-release preparation of pinacidil have been studied in eight normotensive volunteers aged 40–57 years.

Continuous administration of 20 mg b.i.d. pinacidil had no effect on serum pinacidil concentrations measured as AUC (0–9 h), but accumulation of the principal metabolite, pinacidil pyridine-N-oxide was found to occur.

There were no significant changes in erect and supine blood pressure and heart rate from the pretreatment levels on days 1,15 or 29.

Chronic administration of pinacidil caused a significant increase in weight over the total period of study. There were also significant changes in mean sodium (+2.38 mmol/l) and alkaline phosphatase (+15.75 iU/l) from the start to the end of pinacidil therapy but values were within the normal ranges, except for one alkaline phosphatase.

There were significant changes in the following haematological parameters over the period of pinacidil therapy; leukocytes (−1.49 × 109/l), haemoglobin (−0.56 g/dl), MCH (−1.1 pg), MCHC (−1.22 g/dl), platelet MCV (−0.90 fl).

Key words

pinacidil pinacidi pyridine-n-oxide accumulation adverse effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kardel T, Hilden T, Carlsen J, Trap-Jensen J (1981) N″-cyano-N-4-pyridyl-N″-1,2,2,-trimethylpropylguanidine, a new vasodilating agent: acute effect on blood pressure and pharmacokinetics in hypertensive patients. J Cardiovasc Pharmacol 3: 1002–1007Google Scholar
  2. 2.
    Ramsey L, Freestone S (1983) Preliminary evaluation of pinacidil in hypertension. Br J Clin Pharmacol 16: 336–338Google Scholar
  3. 3.
    Ward JW (1984) Pinacidil monotherapy for hypertension. Br J Clin Pharmacol 18: 223–225Google Scholar
  4. 4.
    Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 121–123Google Scholar
  5. 5.
    Caruana MP, Al-Khawaja I, Royston P, Raftery EB (1985) The effects of long-acting pinacidil on intra-arterial blood pressure. Br J Clin Pharmacol 20: 140–143Google Scholar
  6. 6.
    Eilertsen E, Magnussen MP, Petersen HJ, Rastrup-Andersen N, Sorensen H, Arrigoni-Martelli E (1982) Metabolism of the new antihypertensive agent, pinacidil, in rat, dog and man. Xenobiotica 12 [3]: 187–196Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • A. McBurney
    • 1
  • J. A. Henry
    • 2
  • J. W. Ward
    • 1
  1. 1.Department of Clinical PharmacologyGlenfield DGHLeicesterUK
  2. 2.Poisons UnitNew Cross HospitalLondonUK

Personalised recommendations